

Zeman, R.
09/284787

09/284787

FILE 'REGISTRY' ENTERED AT 09:15:24 ON 12 APR 2002

L1 686 S YPYDVPDYA/SQSP

FILE 'CAPLUS' ENTERED AT 09:16:30 ON 12 APR 2002

L2 50 S L1 AND (MOAB OR MAB OR MONOCLON?)
L3 9 S L2 AND (AFFINIT? OR 108M? OR 109M? OR 10#(2W)M)
L4 11 S L1(L) (MOAB OR MAB OR MONOCLON?)
L5 17 S L3 OR L4

L5 ANSWER 1 OF 17 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2001:829541 CAPLUS

DOCUMENT NUMBER: 136:101015

TITLE: Hyper immunoglobulin E response in mice with monoclonal populations of B and T lymphocytes

AUTHOR(S): Curotto de Lafaille, Maria A.; Muriglan, Stephanie; Sunshine, Mary-Jean; Lei, Ying; Kutchukhidze, Nino; Furtado, Glaucia C.; Wensky, Allen K.; Olivares-Villagomez, Danyvid; Lafaille, Juan J.

CORPORATE SOURCE: Program of Molecular Pathogenesis, Skirball Institute for Biomolecular Medicine, New York University School of Medicine, New York, NY, 10016, USA

SOURCE: Journal of Experimental Medicine (2001), 194(9), 1349-1359

CODEN: JEMEAV; ISSN: 0022-1007

PUBLISHER: Rockefeller University Press

DOCUMENT TYPE: Journal

LANGUAGE: English

AB A key event in the pathogenesis of allergies is the prodn. of antibodies of the IgE class. In normal individuals the levels of IgE are tightly regulated, as illustrated by the low serum IgE concn. In addn., multiple immunizations are usually required to generate detectable IgE responses in normal exptl. animals. To define the parameters that regulate IgE prodn. in vivo, we generated mice bearing monoclonal populations of B and T lymphocytes specific for influenza virus hemagglutinin (HA) and chicken ovalbumin (OVA), resp. A single immunization of the monoclonal mice with the cross-linked OVA-HA antigen led to serum IgE levels that reached 30-200 .mu.g/mL. This unusually high IgE response was prevented by the infusion of regulatory .alpha./beta. CD4+ T cells belonging to both CD25+ and CD25- subpopulations. The regulation by the infused T cells impeded the development of fully competent OVA-specific effector/memory Th2 lymphocytes without inhibiting the initial proliferative response of T cells or promoting activation-induced cell death. Our results indicate that hyper IgE responses do not occur in normal individuals due to the presence of regulatory T cells, and imply that the induction of regulatory CD4+ T cells could be used for the prevention of atopy.

IT 92000-73-2DP, ovalbumin conjugates

RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(hyper IgE response in mice with monoclonal populations of B and T lymphocytes response to)

REFERENCE COUNT: 77 THERE ARE 77 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

09/284787

L5 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2001:763224 CAPLUS
DOCUMENT NUMBER: 135:317460
TITLE: Immunoassay of anti-HM1.24 antibody
INVENTOR(S): Kinoshita, Yasuko; Ishikawa, Yuji
PATENT ASSIGNEE(S): Chugai Seiyaku Kabushiki Kaisha, Japan
SOURCE: PCT Int. Appl., 95 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|----------|-----------------|----------|
| WO 2001077362 | A1 | 20011018 | WO 2001-JP2964 | 20010405 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |

PRIORITY APPLN. INFO.: JP 2000-105423 A 20000406
AB A process whereby a highly purified sol. HM1.24 antigen protein can be produced at a high efficiency. Namely, a process for producing a sol. HM1.24 antigen extracellular domain characterized by comprising culturing animal cells transformed by an expression vector which contains an (A1)EF1a promoter and a gene encoding sol. HM1.24 antigen lacking the intracellular domain ligated downstream of the promoter, and isolating and purifying the sol. HM1.24 antigen from the culture.
IT 368511-80-2 368511-81-3
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(amino acid sequence; mol. cloning and purifn. of sol. HM1.24 antigens and monoclonal antibody for immunoassay of sol. HM1.24 antigens)
REFERENCE COUNT: 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 3 OF 17 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2001:396700 CAPLUS
DOCUMENT NUMBER: 135:32749
TITLE: "Bonzo" chemokine receptor antibodies and ligands
INVENTOR(S): Briskin, Michael J.; Murphy, Kristine E.; Wilbanks, Alyson M.; Wu, Lijun
PATENT ASSIGNEE(S): Millennium Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 190 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English

Searcher : Shears 308-4994

09/284787

FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------|-----------------|------------|
| WO 2001037872 | A1 | 20010531 | WO 2000-US32206 | 20001122 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| US 6319675 | B1 | 20011120 | US 1999-449437 | 19991124 |
| PRIORITY APPLN. INFO.: | | | US 1999-449437 | A 19991124 |
| AB The invention relates to an antibody or antigen-binding fragment thereof which binds to the CXC chemokine receptor Bonzo (also referred to as STRL33, TYMSTR, HBMBU14 and CXCR6) and blocks the binding of a ligand e.g., SExCkine (also referred to as chemokine alpha-5 and CXCL16) to the receptor. The invention also relates to a method of identifying agents (mols., compds.) which can bind to Bonzo and inhibit the binding of a ligand (e.g. SExCkine) and/or modulate a function of Bonzo. The invention relates to an antibody or antigen-binding fragment thereof which binds to the CXC chemokine SExCkine and inhibits binding of SExCkine to Bonzo receptor. The invention also relates to targeting mols. which contain a first binding moiety which binds to mammalian Bonzo and a second binding moiety which binds to a mol. expressed on the surface of a target cell. The invention also relates to a method of promoting and/or effectuating the interaction of a Bonzo+ cell and a target cell. The invention further relates to a method of modulating a function of Bonzo, and to the use of the antibodies, antigen-binding fragments, targeting mols. and agents identified by the method of the invention in research, therapeutic, prophylactic and diagnostic methods. | | | | |
| IT 340023-47-4 RL: PRP (Properties) (unclaimed sequence; "Bonzo" chemokine receptor antibodies and ligands) | | | | |
| REFERENCE COUNT: | 2 | THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT | | |
| L5 ANSWER 4 OF 17 CAPLUS COPYRIGHT 2002 ACS | | | | |
| ACCESSION NUMBER: | 2001:265651 CAPLUS | | | |
| DOCUMENT NUMBER: | 134:309702 | | | |
| TITLE: | Human antibodies | | | |
| INVENTOR(S): | Buechler, Joe; Valkirs, Gunars; Gray, Jeff; Lonberg, Nils | | | |
| PATENT ASSIGNEE(S): | Biosite Diagnostics Inc., USA; Genpharm International A Subsidiary of Medarex, Inc. | | | |
| SOURCE: | PCT Int. Appl., 161 pp. CODEN: PIXXD2 | | | |
| DOCUMENT TYPE: | Patent | | | |

Searcher : Shears 308-4994

09/284787

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---------------|------|----------|-----------------|----------|
| WO 2001025492 | A1 | 20010412 | WO 2000-US27237 | 20001002 |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 1999-157415P P 19991002
US 1999-453234 A 19991201

AB The invention uses the power of display selection methods to screen libraries of human Ig genes from nonhuman transgenic animals expressing human Igs. Such screening produces unlimited nos. of high **affinity** human antibodies to any target of interest. The recombinant antibodies can be useful for diagnosis and treatment of infection, inflammation, and cancer. Thus, recombinant anti-interleukin 8 and anti-oxidized troponin antibody heavy and light chains were prepd.

IT 335072-50-9 335072-51-0 335072-52-1
335072-53-2 335072-54-3 335072-55-4
335072-56-5 335072-57-6 335072-59-8
335072-60-1 335072-61-2 335072-62-3
335072-63-4 335072-64-5 335072-65-6
335072-83-8 335072-85-0 335072-86-1
335072-87-2 335072-88-3 335072-89-4
335072-90-7 335072-91-8 335072-92-9
335072-93-0

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(amino acid sequence; display selection of transgenic animal derived human Ig. genes and antibodies for diagnosis and therapy)

IT 122580-22-7

RL: PRP (Properties)
(unclaimed sequence; human antibodies)

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 5 OF 17 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2001:101181 CAPLUS

DOCUMENT NUMBER: 134:159864

TITLE: **Affinity** fluorescent proteins and uses for ligand detection

INVENTOR(S): Matsudaira, Paul T.; Ehrlich, Daniel J.; Zhong, Qiuhui; Freyson, Yelena

PATENT ASSIGNEE(S): Whitehead Institute for Biomedical Research, USA

SOURCE: PCT Int. Appl., 44 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

09/284787

LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----------------------------------------------------------------------------|------|----------|-----------------|----------|
| WO 2001009177 | A2 | 20010208 | WO 2000-US20619 | 20000728 |
| W: CA, JP | | | | |
| RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE | | | | |

PRIORITY APPLN. INFO.: US 1999-146438P P 19990729

AB The present invention is related to an **affinity** fluorescent protein (aFP) comprising a modified fluorescent protein or mol. which comprises a heterologous amino acid sequence, thereby introducing a ligand-activated protein binding site. The modified fluorescent protein displays an altered spectral property when the binding site is engaged with ligand relative to the spectral property displayed when the binding site is not engaged by ligand. The hexapeptide Leu-Glu-Pro-Arg-Ala-Ser which contains 3 restriction enzyme sites (XhoI-AvrI-NheI) is useful for identifying fluorescent insensitive sites in the green fluorescent protein (GFP). An epitope from hemagglutinin (HA tag comprising Tyr-Pro-Tyr-Asp-Val-Pro-Asp-Tyr-Ala) that is recognized by the **monoclonal** antibody 12CA5 is inserted into between residues Gln157-Lys158 and/or Glu172-Asp173 and/or at the C-terminus of GFP; a Ser-147-Pro substitution is introduced into GFP for improved stability. The present invention also relates to an aFP expression cassette comprising a modified fluorescent protein nucleic acid sequence operatively linked to expression control sequences, wherein the modified fluorescent protein sequence comprises a recombinant peptide which comprises restriction endonuclease sites. The present invention also relates to a method of detecting the presence of a target ligand in a mixt. of macromols. Also encompassed by the present invention is a method of detecting the occurrence of a target ligand in a cell (e.g., a macrophage, a yeast cell).

IT 324831-40-5P 324831-41-6P 324831-42-7P
324831-43-8P 324831-44-9P 324831-45-0P

RL: ARG (Analytical reagent use); BPN (Biosynthetic preparation);
PRP (Properties); ANST (Analytical study); BIOL (Biological study);
PREP (Preparation); USES (Uses)
(amino acid sequence; **affinity** fluorescent proteins and
uses for ligand detection)

IT 92000-76-5

RL: BUU (Biological use, unclassified); BIOL (Biological study);
USES (Uses)
(hemagglutinin **affinity** tag; **affinity**
fluorescent proteins and uses for ligand detection)

L5 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2000:911306 CAPLUS

DOCUMENT NUMBER: 134:70371

TITLE: ANTI-.alpha.v.beta.3 recombinant human
antibodies, nucleic acids encoding same and
methods of use

INVENTOR(S): Huse, William D.; Wu, Herren

PATENT ASSIGNEE(S): Applied Molecular Evolution, USA

SOURCE: PCT Int. Appl., 136 pp.
CODEN: PIXXD2

09/284787

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|----------|-----------------|----------|
| WO 2000078815 | A1 | 20001228 | WO 2000-US17454 | 20000623 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TZ, UA, UG, US, VZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| EP 1189946 | A1 | 20020327 | EP 2000-941707 | 20000623 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO | | | | |
| NO 2001006243 | A | 20020215 | NO 2001-6243 | 20011219 |
| PRIORITY APPLN. INFO.: US 1999-339922 A2 19990624 | | | | |
| WO 2000-US17454 W 20000623 | | | | |
| AB The invention provides enhanced LM609 grafted antibodies exhibiting selective binding affinity to .alpha.v.beta.3, or a functional fragment thereof. The invention also provides nucleic acid mols. encoding the enhanced LM609 grafted antibodies. Addnl. provided are methods of inhibiting a function of .alpha.v.beta.3 by contacting .alpha.v.beta.3 with an enhanced LM609 grafted antibody. | | | | |
| IT 122580-22-7 | | | | |
| RL: PRP (Properties) (unclaimed sequence; aNTI-.alpha.v.beta.3 recombinant human antibodies, nucleic acids encoding same and methods of use) | | | | |
| REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT | | | | |

L5 ANSWER 7 OF 17 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2000:475948 CAPLUS
DOCUMENT NUMBER: 133:103704
TITLE: Production of monoclonal antibodies with hybridomas created by fusion of recombinant antibody binding protein-producing myeloma cells and B lymphocytes
INVENTOR(S): Breitling, Frank; Poustka, Annemarie; Moldenhauer, Gerhard
PATENT ASSIGNEE(S): Deutsches Krebsforschungszentrum Stiftung des Oeffentlichen Rechts, Germany
SOURCE: Ger. Offen., 22 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------------|------|------|-----------------|------|
|------------|------|------|-----------------|------|

Searcher : Shears 308-4994

09/284787

DE 19900635 A1 20000713 DE 1999-19900635 19990111
WO 2000042176 A1 20000720 WO 2000-DE79 20000111
W: JP, US
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC,
NL, PT, SE
EP 1141271 A1 20011010 EP 2000-903509 20000111
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC,
PT, IE, FI

PRIORITY APPLN. INFO.: DE 1999-19900635 A 19990111
WO 2000-DE79 W 20000111

AB A procedure for the prodn. and selection of monoclonal antibodies is disclosed which comprises fusion of B-lymphocytes with myeloma cells to produce antibody-producing hybridoma cells. The hybridoma cells are recombinant cells which express an antibody binding protein on their surface. The hybridomas producing the desired antibodies are selected based on the antigen specificity of the antibodies displayed on the hybridoma surface. Thus, recombinant hybridoma cells expressing a chimeric protein contg. the mouse Ig .kappa. chain signal peptide fused to 2 antibody-binding domains of protein G fused to the transmembrane domain of CD52 were prepd. These recombinant hybridomas were fused to anti-urokinase antibody-producing B lymphocytes. The hybridomas displaying the desired antibodies on their surface were selected by fluorescence-activated cell sorting after incubating the cells with urokinase-biotin and streptavidin-FITC.

IT 282119-67-9

RL: BUU (Biological use, unclassified); PRP (Properties); BIOL (Biological study); USES (Uses)
(amino acid sequence; prodn. of monoclonal antibodies with hybridomas created by fusion of recombinant antibody binding protein-producing myeloma cells and B lymphocytes)

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 8 OF 17 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1998:716252 CAPLUS
DOCUMENT NUMBER: 129:326944
TITLE: Polyvalent and polyclonal antibody phage display libraries
INVENTOR(S): Gray, Jeff; Buechler, Joe; Valkirs, Gunars
PATENT ASSIGNEE(S): Biosite Diagnostics, Inc., USA
SOURCE: PCT Int. Appl., 102 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------|-----------------|----------|
| WO 9847343 | A2 | 19981029 | WO 1998-US6704 | 19980403 |
| WO 9847343 | A3 | 19981210 | | |
| W: | AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, | | | |

Searcher : Shears 308-4994

09/284787

MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK,
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG
US 6057098 A 20000502 US 1997-832985 19970404
AU 9887557 A1 19981113 AU 1998-87557 19980403
EP 985033 A2 20000315 EP 1998-939053 19980403
R: CH, DE, FR, GB, IT, LI, NL
US 6348318 B1 20020219 US 1998-54918 19980403
PRIORITY APPLN. INFO.: US 1997-832985 A 19970404
US 1997-835159 A 19970404
US 1997-44292P P 19970404
US 1997-832935 A 19970404
WO 1998-US6704 W 19980403

AB The invention is directed to inter alia two related but self-sufficient improvements in conventional display methods. The first improvement provides methods of enriching conventional display libraries for members displaying more than one copy of a polypeptide prior to **affinity** screening of such libraries with a target of interest. These methods can achieve diverse populations in which the vast majority of members retaining full-length coding sequences encode polypeptides having specific **affinity** for the target. In a second aspect, the invention provides methods of subcloning nucleic acids encoding displayed polypeptides of enriched libraries from a display vector to an expression vector without the need for clonal isolation of individual members. The expression vector for subcloning of **monoclonal** and polyclonal antibody genes from a phage-display vector was developed that is efficient, does not substantially bias the polyclonal population, and can select for vector contg. an insert capable of restoring antibiotic resistance. The vector is a modified pBR322 plasmid, designated pBRncoH3, that contains an arabinosase promoter, ampicillin resistance (.beta.-lactamase) gene, a partial tetracycline resistance gene, a pelB (pectate lyase) signal sequence, and NcoI and HindIII restriction sites. These methods result in polyclonal libraries of antibodies and other polypeptides for use, e.g., as diagnostics or therapeutic reagents.

IT 122580-22-7P

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of 7F11 **monoclonal** antibodies; polyvalent and polyclonal antibody phage display libraries)

L5 ANSWER 9 OF 17 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1998:711658 CAPLUS

DOCUMENT NUMBER: 130:47580

TITLE: Epitope tag mapping of the extracellular and cytoplasmic domains of the rat parathyroid hormone (PTH)/PTH-related peptide receptor

AUTHOR(S): Xie, Lin Y.; Abou-Samra, Abdul B.

CORPORATE SOURCE: Endocrine Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA, 02114, USA

SOURCE: Endocrinology (1998), 139(11), 4563-4567

CODEN: ENDOAO; ISSN: 0013-7227

PUBLISHER: Endocrine Society

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The PTH/PTH-related peptide (PTHrP) receptor is predicted to span

09/284787

the plasma membrane seven times with an amino-terminal extracellular extension and a cytoplasmic carboxyl-terminal tail. To assess this prediction, we inserted 10- or 9-amino acid epitope tags from c-myc or Haemophilus influenza hemagglutinin (HA), which are recognized by the **monoclonal** antibodies 9E10 and 12Ca5, resp., in different extracellular and cytoplasmic regions of the receptor and examd. the immunoreactivity of the epitopes in intact and permeabilized cells. The data show that the epitopes were well tolerated when introduced into the E2 region of the extracellular amino-terminus (E2-myc and E2-HA), in the first extracellular loop (EL1), in the second and third cytoplasmic loops (CL2c and CL3), or in the carboxyl-terminal tail (T-myc). Receptors tagged at these locations were well expressed, bound PTH with high **affinity**, and increased cAMP accumulation with a good efficiency. Receptors tagged in the second and third extracellular loops (EL2c and EL3c) or the first cytoplasmic loop (CL1c) bound the PTH radioligand with a low **affinity**, stimulated cAMP accumulation with a low efficiency, and had low expression levels. The receptors tagged on presumed extracellular regions, E2-myc, E2-HA, EL1, EL2c, and EL3c, were readily detected on the surface of intact cells with the **monoclonal** antibody against the epitope tag. In contrast, receptors tagged with the c-myc epitope in the cytoplasmic loops (CL1c, CL2c, and CL3) or in the carboxyl-terminal tail (T-myc) did not show any 9E10 binding in intact cells. These receptors, however, were well expressed on the cell surface, as detected by the binding of the **monoclonal** antibody, 12Ca5, to the HA tag that was introduced into the E2 region of these constructs. The c-myc epitopes, however, became accessible after permeabilization of the cell membrane. In conclusion, these data provide exptl. evidence for the sidedness of the extracellular and cytoplasmic domains of the PTH/PTHrP receptor.

IT 217323-97-2

RL: BUU (Biological use, unclassified); PRP (Properties); BIOL (Biological study); USES (Uses)
(plasmid E2-HA; epitope tag mapping of the extracellular and cytoplasmic domains of the rat parathyroid hormone (PTH)/PTH-related peptide receptor)

REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 10 OF 17 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1998:682608 CAPLUS

DOCUMENT NUMBER: 129:313112

TITLE: Methods for concentrating and detecting ligands using magnetic particles

INVENTOR(S): Valkirs, Gunars E.

PATENT ASSIGNEE(S): Biosite Diagnostics, Inc., USA

SOURCE: PCT Int. Appl., 49 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------------|------|----------|-----------------|----------|
| WO 9845684 | A1 | 19981015 | WO 1998-US6605 | 19980403 |

Searcher : Shears 308-4994

09/284787

W: CA, JP

RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC,
NL, PT, SE

EP 972183 A1 20000119 EP 1998-915262 19980403

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC,
PT, IE, FI

US 6348318 B1 20020219 US 1998-54918 19980403

PRIORITY APPLN. INFO.:

US 1997-44292P P 19970404

US 1997-832935 A 19970404

US 1997-832985 A 19970404

US 1997-835159 A 19970404

WO 1998-US6605 W 19980403

AB This invention provides methods, compns. and kits for concg. target ligands, including microorganisms, from samples, including biol. samples. The methods involve the use of magnetic particles to conc. the target analytes. Also provided are methods, compns. and kits for detecting the presence of target ligands in samples. A high-sensitivity assay for Clostridium difficile toxin A used magnetic beads to conc. the toxin before detecting the toxin by sandwich ELISA. Prepn. of the monoclonal antibodies and reagents for the sepn. and assay are described.

IT 214681-43-3DP, conjugates with KLH and BSA

RL: BPR (Biological process); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); PROC (Process)

(in prepn. of monoclonal antibodies; methods for concg. and detecting ligands using magnetic particles)

IT 122580-22-7

RL: RCT (Reactant)

(in prepn. of monoclonal antibodies; methods for concg. and detecting ligands using magnetic particles)

IT 214681-43-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)

(in prepn. of monoclonal antibodies; methods for concg. and detecting ligands using magnetic particles)

L5 ANSWER 11 OF 17 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1998:256196 CAPLUS

DOCUMENT NUMBER: 128:307529

TITLE: Monoclonal antibodies against epitope
YPYDVPDYA and a procedure for their production
and use

INVENTOR(S): Emrich, Thomas; Hinzpeter, Matthias; Grol,
Michael

PATENT ASSIGNEE(S): Boehringer Mannheim G.m.b.H., Germany

SOURCE: Ger. Offen., 6 pp.

CODEN: GWXXBX

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---------------------------------------------------------------------------|------|----------|------------------|----------|
| DE 19643314 | A1 | 19980423 | DE 1996-19643314 | 19961021 |
| WO 9817691 | A1 | 19980430 | WO 1997-EP5783 | 19971020 |
| W: AU, CA, CN, IL, JP, KR, NO, NZ, US | | | | |
| RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE | | | | |

Searcher : Shears 308-4994

09/284787

AU 9749485 A1 19980515 AU 1997-49485 19971020
EP 932625 A1 19990804 EP 1997-912204 19971020
R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, NL, SE, IE, FI
JP 2001502902 T2 20010306 JP 1998-518952 19971020
PRIORITY APPLN. INFO.: DE 1996-19643314 A 19961021
 WO 1997-EP5783 W 19971020

AB The invention concerns **monoclonal** antibodies against the epitope YPYDVDPYA derived from hemagglutinin of human influenza virus. The **monoclonal** antibodies are suitable for detection and isolation of native hemagglutinin of human influenza virus, of modified hemagglutinin or of hemagglutinin-fusion proteins and exhibit an **affinity** exceeding **108M**-1, particularly of 109 to 1010M-1.

IT **206654-11-7P 206654-13-9P**
RL: BPR (Biological process); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); PROC (Process)

(coupled with keyhole limpet hemocyanin; **monoclonal** antibodies against epitope YPYDVDPYA from influenza virus hemagglutinin and a procedure for their prodn. and use)

IT **92000-76-5**
RL: BPR (Biological process); PRP (Properties); BIOL (Biological study); PROC (Process)
(**monoclonal** antibodies against epitope YPYDVDPYA from influenza virus hemagglutinin and a procedure for their prodn. and use)

L5 ANSWER 12 OF 17 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1995:367540 CAPLUS

DOCUMENT NUMBER: 122:185340

TITLE: Monoclonal antibodies to peptides of the stem region of hemagglutinin subtypes H1N1 and H2N2 of human influenza A virus and their therapeutic and diagnostic uses

INVENTOR(S): Okuno, Yoshinobu; Isegawa, Yuiji; Sasao, Fuyoko; Ueda, Shigeharu

PATENT ASSIGNEE(S): Takara Shuzo Co. Ltd., Japan

SOURCE: Eur. Pat. Appl., 68 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|-----------------------------------|------|----------|-----------------|----------|
| EP 621339 | A2 | 19941026 | EP 1994-302819 | 19940420 |
| EP 621339 | A3 | 19951129 | | |
| EP 621339 | B1 | 20011024 | | |
| R: CH, DE, ES, FR, GB, IT, LI, SE | | | | |
| JP 07089992 | A2 | 19950404 | JP 1994-70194 | 19940316 |
| JP 3037554 | B2 | 20000424 | | |
| CA 2121559 | AA | 19941021 | CA 1994-2121559 | 19940418 |

PRIORITY APPLN. INFO.: JP 1993-115216 A 19930420
 JP 1994-70194 A 19940316

AB Neutralizing monoclonal antibodies to an antigenic domain of the stem region of human influenza A virus hemagglutinins identify an antigenic domain of hemagglutinin mols. of H1N1 and H2N2 subtypes

09/284787

but not of H3N2 and has no neutralization activity against it. A polypeptide with substantially the same antigenicity as this domain is prepd., e.g. by expression of the coding sequence in Escherichia coli, for use in vaccines. This antibody is useful in the diagnosis and treatment of influenza A virus, while the polypeptides are useful as a vaccine. The peptide was identified as the epitope recognized by a monoclonal antibody. The construction of expression vectors for manuf. of the peptides is described. Mice inoculated with one of these stem polypeptides 10 .mu.g/animal in each of three injections at weekly intervals showed greater resistance to challenge with a 14 day survival rate of 80% after challenge with 2.times.10³ FFU of virus. The control group showed a 14 day survival rate of 55%.

IT 76082-66-1, Hemagglutinin (influenza virus A/Aichi/2/68 clone X31 precursor protein moiety reduced)
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(amino acid sequence; **monoclonal** antibodies to the stem region of hemagglutinin subtypes H1N1 and H2N2 of human influenza A virus and their therapeutic and diagnostic uses)

L5 ANSWER 13 OF 17 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1991:492883 CAPLUS

DOCUMENT NUMBER: 115:92883

TITLE: Synthesis, conformational properties, and antibody recognition of peptides containing .beta.-turn mimetics based on .alpha.-alkylproline derivatives

AUTHOR(S): Hinds, Mark G.; Welsh, John H.; Brennand, David M.; Fisher, J.; Glennie, Martin J.; Richards, Nigel G. J.; Turner, David L.; Robinson, John A.

CORPORATE SOURCE: Chem. Dep., Univ. Southampton, Southampton, SO9 5NH, UK

SOURCE: J. Med. Chem. (1991), 34(6), 1777-89
CODEN: JMCMAR; ISSN: 0022-2623

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 115:92883

GI For diagram(s), see printed CA Issue.

AB Peptide recognition by **monoclonal** antibodies may provide a useful model for drug development, in particular to test the effects of conformational restriction on ligand binding. We have tested the influence of novel peptide mimetics upon conformation and binding **affinity** for the case of **monoclonal** antibodies raised to a peptide antigen which displays a preference for a .beta.-turn conformation in aq. soln. Two **monoclonals** were isolated that recognized the peptide Ac-Tyr-Pro-Tyr-Asp-Val-Pro-Asp-Tyr-Ala-OH specifically at the .beta.-turn formed by Tyr-Pro-Tyr-Asp. Peptides analogs I and II were prepd. contg. mimetics designed to stabilize this conformation. II contains a spirocyclic .gamma.-lactam bridge between the .alpha.-position of proline-2 and the N atom of the tyrosine-3, while I contains (S)-.alpha.-methylproline at position 2. NMR spectroscopy and mol. modeling suggest that both analogs adopt reverse-turn conformations stabilized relative to that in the native sequence. For the (S)-.alpha.-methylproline analog binding to both **monoclonal** antibodies was substantially improved, compared with the native antigen, whereas the .gamma.-lactam analog II was not recognized by

09/284787

either antibody. Quant. equil. ultrafiltration binding assays showed that the **affinities** of the (S)-.alpha.-methylproline analog I for the two antibodies were improved over those measured with the native antigen by -2,3 and -0.65 kcal/mol. The origins of these free energy differences cannot be explained wholly on the basis of presumed extra hydrophobic contacts between the new Me substituent and the antigen binding sites. The increased conformational stability of the analog plays a decisive role, implying that the reverse turn detected in the native antigen, possibly a type-I turn, is important for recognition by the two antibodies.

IT 133373-22-5P 133373-25-8P 133373-26-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
IT 129970-92-9P 130203-49-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn., conformation, and antibody-binding activity of)

L5 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1991:469641 CAPLUS
DOCUMENT NUMBER: 115:69641
TITLE: Probing the role of proline as a recognition
element in peptide antigens [Erratum to document
cited in CA113(21):189276k]
AUTHOR(S): Richards, Nigel G. J.; Hinds, Mark G.; Brennand,
David M.; Glennie, Martin J.; Welsh, John M.;
Robinson, John A.
CORPORATE SOURCE: Dep. Chem., Univ. Southampton, Southampton, SO9
5NH, UK
SOURCE: Biochem. Pharmacol. (1991), 41(5), 849
CODEN: BCPA6; ISSN: 0006-2952
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Errors in the stereochem. of structures 1-4 have been cor. The
errors were reflected in the index entries.
IT 92000-76-5 129970-92-9 130203-49-5
RL: BIOL (Biological study)
(**monoclonal** antibody binding to, conformation in
relation to (Erratum))

L5 ANSWER 15 OF 17 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1990:589276 CAPLUS
DOCUMENT NUMBER: 113:189276
TITLE: Probing the role of proline as a recognition
element in peptide antigens
AUTHOR(S): Richards, Nigel G. J.; Hinds, Mark G.; Brennand,
David M.; Glennie, Martin J.; Welsh, John M.;
Robinson, John A.
CORPORATE SOURCE: Dep. Chem., Univ. Southampton, Southampton, SO9
5NH, UK
SOURCE: Biochem. Pharmacol. (1990), 40(1), 119-23
CODEN: BCPA6; ISSN: 0006-2952
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The recognition of flexible, linear oligopeptides by monoclonal
antibodies is sensitive to the entropy penalty incurred when the
peptide becomes constrained to a well-defined region of its
conformation space upon binding. This aspect recognition is often

09/284787

difficult to probe using natural amino acid replacements due to the difficulty of maintaining the steric and electrostatic features of the natural substrate for the receptor. In utilizing the non-natural analogs of S- proline, the overall charge of the peptide analogs was maintained as were the no. of hydrogen bonding sites available for interaction with the receptor. However, as judged by NMR methods, these non-natural amino acids modified the conformational mobilities of analogs. Their use as replacement for S-proline in other biol. important substrates, such as bradykinin, may allow some detn. of the relative importance of dynamic properties in systems involving the interaction of flexible proline-contg. peptides with cellular receptors.

IT 130203-47-3 130203-48-4 130203-49-5

RL: BIOL (Biological study)

(**monoclonal** antibody binding to, conformation in relation to)

L5 ANSWER 16 OF 17 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1989:532040 CAPLUS

DOCUMENT NUMBER: 111:132040

TITLE: Exact amino acid involvement in the interactions of peptide antigens with monoclonal antibodies
Houghten, Richard A.

AUTHOR(S):
CORPORATE SOURCE: Dep. Mol. Biol., Scripps Clin., La Jolla, CA, 92037, USA

SOURCE: Banbury Rep. (1988), 29(Ther. Pept. Proteins), 151-61

CODEN: BANRDU; ISSN: 0198-0068

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Synthetic peptides prepd. by the simultaneous multiple peptide synthesis (SMPS) method were used to study binding to monoclonal antibodies. The majority of determinants that appear to be linear are 6 residues in length, with a range from 2 to 8; addnl. amino acids influence the binding. Peptides with substitutions have decreased, or at best, equal antibody binding as compared to the original peptide. It is suggested that SMPS is better than the use of permanent support-bound peptides for this type of study.

IT 92000-68-5 92000-73-2 92000-76-5

122580-20-5 122580-21-6

RL: BIOL (Biological study)

(antigenic, **monoclonal** antibodies interaction with)

L5 ANSWER 17 OF 17 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1987:3593 CAPLUS

DOCUMENT NUMBER: 106:3593

TITLE: Structural analysis of antipeptide antibodies against influenza virus hemagglutinin

AUTHOR(S): Wilson, Ian A.; Bergmann, Katherine F.; Stura, Enrico A.

CORPORATE SOURCE: Res. Inst., Scripps Clin., La Jolla, CA, 92037, USA

SOURCE: Vaccines 86, New Approaches Immun., [Proc. Conf.] (1986), Meeting Date 1985, 33-7.
Editor(s): Brown, Fred; Chanock, Robert M.; Lerner, Richard Alan. Cold Spring Harbor Lab.: Cold Spring Harbor, N. Y.
CODEN: 55ENAN

09/284787

DOCUMENT TYPE: Conference

LANGUAGE: English

AB **Monoclonal** antibodies specific for a synthetic peptide corresponding to influenza virus hemagglutinin (HA) residues 75-110 were generated. **Affinity** consts. for 6 **monoclonal** antibodies to peptides of varying lengths around residues HA 98-106 ranged from 106 to 108. Peptides that contained the complete binding site had the highest **affinities**. Important antigenic residues are contained in HA 100-106/7, since peptides that did not contain these residues did not bind. Crystals of a **monoclonal** antibody Fab fragment and HA 88-110 were very thin. They were **monoclonic**, space group P21, with cell dimensions $a = 60.4$, $b = 72.0$, $c = 68.9$.ANG., and $\beta = 104.5$.degree..

IT 92000-68-5

RL: BIOL (Biological study)
(**monoclonal** antibody Fab fragment complexes, crystal structure of)

IT 87244-32-4

RL: BIOL (Biological study)
(of hemagglutinin from influenza virus, **monoclonal** antibodies to, specificity of)

E1 THROUGH E54 ASSIGNED

FILE 'REGISTRY' ENTERED AT 09:23:45 ON 12 APR 2002

L6 52 SEA FILE=REGISTRY ABB=ON PLU=ON (122580-22-7/BI OR
92000-76-5/BI OR 130203-49-5/BI OR 129970-92-9/BI OR
214681-43-3/BI OR 92000-68-5/BI OR 92000-73-2/BI OR
122580-20-5/BI OR 122580-21-6/BI OR 130203-47-3/BI OR
130203-48-4/BI OR 133373-22-5/BI OR 133373-25-8/BI OR
133373-26-9/BI OR 206654-11-7/BI OR 206654-13-9/BI OR
217323-97-2/BI OR 282119-67-9/BI OR 324831-40-5/BI OR
324831-41-6/BI OR 324831-42-7/BI OR 324831-43-8/BI OR
324831-44-9/BI OR 324831-45-0/BI OR 335072-50-9/BI OR
335072-51-0/BI OR 335072-52-1/BI OR 335072-53-2/BI OR
335072-54-3/BI OR 335072-55-4/BI OR 335072-56-5/BI OR
335072-57-6/BI OR 335072-59-8/BI OR 335072-60-1/BI OR
335072-61-2/BI OR 335072-62-3/BI OR 335072-63-4/BI OR
335072-64-5/BI OR 335072-65-6/BI OR 335072-83-8/BI OR
335072-85-0/BI OR 335072-86-1/BI OR 335072-87-2/BI OR
335072-88-3/BI OR 335072-89-4/BI OR 335072-90-7/BI OR
335072-91-8/BI OR 335072-92-9/BI OR 335072-93-0/BI OR
340023-47-4/BI OR 368511-80-2/BI OR 368511-81-3/BI OR
76082-66-1/BI OR 87244-32-4/BI)

=> s 16 and 11

L7 52 L6 AND L1

L7 ANSWER 1 OF 52 REGISTRY COPYRIGHT 2002 ACS

RN 368511-81-3 REGISTRY

CN Hemagglutinin (influenza virus fragment) fusion protein with antigen
HM1.24 (human soluble extracellular domain 115-amino acid fragment)
(9CI) (CA INDEX NAME)

OTHER NAMES:

CN 19: PN: WO0177362 SEQID: 19 claimed protein

CI MAN

SQL 126

Searcher : Shears 308-4994

09/284787

SEQ 1 YPYDVDPDYAG TNSEACRDGL RAVMECRNVT HLLQQELTEA QKGFQDVEAQ

=====

51 AATCNHTVMA LMASLDAEKA QGQKKVEELE GEITTLNHKL QDASAEVERL
101 RRENQVLSVR IADKKYYPSS QDSSSA

HITS AT: 1-9

REFERENCE 1: 135:317460

L7 ANSWER 2 OF 52 REGISTRY COPYRIGHT 2002 ACS

RN 368511-80-2 REGISTRY

CN Hemagglutinin (influenza virus fragment) fusion protein with antigen
HM1.24 (human soluble extracellular domain 132-amino acid fragment)
(9CI) (CA INDEX NAME)

OTHER NAMES:

CN 18: PN: WO0177362 SEQID: 18 claimed protein

CI MAN

SQL 143

SEQ 1 YPYDVDPDYAG TNSEACRDGL RAVMECRNVT HLLQQELTEA QKGFQDVEAQ

=====

51 AATCNHTVMA LMASLDAEKA QGQKKVEELE GEITTLNHKL QDASAEVERL
101 RRENQVLSVR IADKKYYPSS QDSSSAAAPQ LLIVLLGLSA LLQ

HITS AT: 1-9

REFERENCE 1: 135:317460

L7 ANSWER 3 OF 52 REGISTRY COPYRIGHT 2002 ACS

RN 340023-47-4 REGISTRY

CN L-Leucine, L-cysteinyl-L-tyrosyl-L-prolyl-L-tyrosyl-L-.alpha.-
aspartyl-L-valyl-L-prolyl-L-.alpha.-aspartyl-L-tyrosyl-L-alanyl-L-
seryl- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 14: PN: WO0137872 SEQID: 11 unclaimed sequence

CN 5: PN: WO0138874 SEQID: 5 unclaimed sequence

SQL 12

SEQ 1 CYPYDVDPDYA SL

=====

HITS AT: 2-10

REFERENCE 1: 135:32749

REFERENCE 2: 134:362240

L7 ANSWER 4 OF 52 REGISTRY COPYRIGHT 2002 ACS

RN 335072-93-0 REGISTRY

CN Immunoglobulin, anti-(troponin) (human clone 3E9 .kappa.-chain V-J-C
region N-terminal fragment) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 98: PN: WO0125492 PAGE: 121 claimed sequence

CI MAN

SQL 224

SEQ 1 ELVMTQSPSS LSASVGDRVT ITCRASQGIS SWLAWYQQKP EKAPKSLIYA

51 ASSLQSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YNSYPITFGQ
101 GTRLEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLDNFY PREAKVQWKV
151 DNALQSGNSQ ESVTEQDSKD STYLSSTLT LSKADYEKHK VYACEVTHQG

09/284787

201 LSSPVTKSFN RGESYPYDVP DYAS

=====

HITS AT: 215-223

REFERENCE 1: 134:309702

L7 ANSWER 5 OF 52 REGISTRY COPYRIGHT 2002 ACS

RN 335072-92-9 REGISTRY

CN Immunoglobulin, anti-(troponin) (human clone 3E8 .kappa.-chain V-J-C region N-terminal fragment) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 97: PN: WO0125492 PAGE: 121 claimed sequence

CI MAN

SQL 224

SEQ 1 AIQLTQSPSS LSASVGDRVT ITCRASQGIS SALAWYQQKP EKAPKLLIYD
51 ASSLESGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YNSYPWTFGQ
101 GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV
151 DNALQSGNSQ ESVTEQDSKD STYLSSTLT LSKADYKHK VYACEVTHQG
201 LSSPVTKSFN RGESYPYDVP DYAS

=====

HITS AT: 215-223

REFERENCE 1: 134:309702

L7 ANSWER 6 OF 52 REGISTRY COPYRIGHT 2002 ACS

RN 335072-91-8 REGISTRY

CN Immunoglobulin, anti-(troponin) (human clone 3E3 .kappa.-chain V-J-C region N-terminal fragment) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 95: PN: WO0125492 PAGE: 121 claimed sequence

CI MAN

SQL 224

SEQ 1 DIQMIQSPSS PSASVGDRVT ITCRASQGIS SALAWYQQKP GKAPKLLIYD
51 ASSLESGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YNSYPLTFGG
101 GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV
151 DNALQSGNSQ ESVTEQDSKD STYLSSTLT LSKADYKHK VYACEVTHQG
201 LSSPVTKSFN RGESYPYDVP DYAS

=====

HITS AT: 215-223

REFERENCE 1: 134:309702

L7 ANSWER 7 OF 52 REGISTRY COPYRIGHT 2002 ACS

RN 335072-90-7 REGISTRY

CN Immunoglobulin, anti-(troponin) (human clone 3E2 .kappa.-chain V-J-C region N-terminal fragment) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 94: PN: WO0125492 PAGE: 121 claimed sequence

CI MAN

SQL 224

SEQ 1 NIQMTQSPSS LSASVGDRVT ITCRASQGIS SWLAWYQQKP EKAPKSLIYA
51 ASSLQSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YNSYPFTFGP
101 GTKVDIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV
151 DNALQSGNSQ ESVTEQDSKD STYLSSTLT LSKADYKHK VYACEVTHQG
201 LSSPVTKSFN RGESYPYDVP DYAS

09/284787

HITS AT: 215-223

REFERENCE 1: 134:309702

L7 ANSWER 8 OF 52 REGISTRY COPYRIGHT 2002 ACS
RN 335072-89-4 REGISTRY
CN Immunoglobulin, anti-(troponin) (human clone 3E1 .kappa.-chain V-J-C
region N-terminal fragment) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 89: PN: WO0125492 PAGE: 121 claimed sequence
CN 96: PN: WO0125492 PAGE: 121 claimed sequence
CN Immunoglobulin, anti-(troponin) (human clone 3E4 .kappa.-chain V-J-C
region N-terminal fragment)
CI MAN
SQL 224

SEQ 1 EIVMTQSPGT LSLSPGERAT LSCRASQSVS SRYLAWYQQK PGQAPRLLIY
51 GASSRATGIP DRFSGSGSGT DFTLAISRLE PEDFAVYFCQ QYGSSITFGQ
101 GTRLEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV
151 DNALQSGNSQ ESVTEQDSKD STYLSSTLT LSKADYEKHK VYACEVTHQG
201 LSSPVTKSFN RGESYPYDVP DYAS

HITS AT: 215-223

REFERENCE 1: 134:309702

L7 ANSWER 9 OF 52 REGISTRY COPYRIGHT 2002 ACS
RN 335072-88-3 REGISTRY
CN Immunoglobulin, anti-(troponin) (human clone 1CE8 .kappa.-chain
V-J-C region N-terminal fragment) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 92: PN: WO0125492 PAGE: 121 claimed sequence
CI MAN
SQL 224

SEQ 1 ELVMTQTPLS LSLSPGERAT LSCRASQNVY SYLAWYQQKP GQAPRLLIYD
51 ASNRAPGIPA RFSGSGSGTD FTLTISSLEP EDFAVYYCQQ RTNWPWTFGQ
101 GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV
151 DNALQSGNSQ ESVTEQDSKD STYLSSTLT LSKADYEKHK VYACEVTHQG
201 LSSPVTKSFN RGESYPYDVP DYAS

HITS AT: 215-223

REFERENCE 1: 134:309702

L7 ANSWER 10 OF 52 REGISTRY COPYRIGHT 2002 ACS
RN 335072-87-2 REGISTRY
CN Immunoglobulin, anti-(troponin) (human clone 1CD7 .kappa.-chain
V-J-C region N-terminal fragment) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 91: PN: WO0125492 PAGE: 121 claimed sequence
CI MAN
SQL 224

SEQ 1 ELVMTQSPAT LSLSPGERAT LSCRASQSIY NYLAWYQQKP GQAPRLLIYD
51 ASNRATGIPA RFSGSGSGTD FTLTISSLEP EDFAVYYCQQ RTNWPWTFGQ
101 GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV

09/284787

151 DNALQSGNSQ ESVTEQDSKD STYLSSTLT LSKADYKHK VYACEVTHQG
201 LSSPVTKSFN RGESYPYDVP DYAS
=====

HITS AT: 215-223

REFERENCE 1: 134:309702

L7 ANSWER 11 OF 52 REGISTRY COPYRIGHT 2002 ACS
RN 335072-86-1 REGISTRY
CN Immunoglobulin, anti-(troponin) (human clone 1CC8 .kappa.-chain
V-J-C region N-terminal fragment) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 90: PN: WO0125492 PAGE: 121 claimed sequence

CI MAN

SQL 224

SEQ 1 EIVLTQSPGT LSLSPGERAT LSCRASQSIY NYLAWYQQKP GQAPRLLIYD
51 ASNRATGIPA RFSGSGSGTD FTLTISSLEP EDFAVYYCQQ RTNWPWTFGQ
101 GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV
151 DNALQSGNSQ ESVTEQDSKD STYLSSTLT LSKADYKHK VYACEVTHQG
201 LSSPVTKSFN RGESYPYDVP DYAS
=====

HITS AT: 215-223

REFERENCE 1: 134:309702

L7 ANSWER 12 OF 52 REGISTRY COPYRIGHT 2002 ACS
RN 335072-85-0 REGISTRY
CN Immunoglobulin, anti-(troponin) (human clone 1CC6 .kappa.-chain
V-J-C region N-terminal fragment) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 93: PN: WO0125492 PAGE: 121 claimed sequence

CI MAN

SQL 224

SEQ 1 ELVMTQTPLS LSLSPGERAT LSCRASQSIY NYLAWYQQKP GQAPRLLIYD
51 ASNRATGIPA RFSGSGSGTD FTLTISSLEP EDFAVYYCQQ RTNWPWTFGQ
101 GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV
151 DNALQSGNSQ ESVTEQDSKD STYLSSTLT LSKADYKHK VYACEVTHQG
201 LSSPVTKSFN RGESYPYDVP DYAS
=====

HITS AT: 215-223

REFERENCE 1: 134:309702

L7 ANSWER 13 OF 52 REGISTRY COPYRIGHT 2002 ACS
RN 335072-83-8 REGISTRY
CN Immunoglobulin, anti-(troponin) (human clone 1CB1 .kappa.-chain
V-J-C region N-terminal fragment) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 87: PN: WO0125492 PAGE: 121 claimed protein

CI MAN

SQL 224

SEQ 1 EIVMTQSPAT LSLSPGERAT LSCRASQSVY SYLVWYQQKP GQAPRLLIYD
51 ASNRATGIPA RFSGSGSGTD FTLTISSLEP EDFAFYYCQQ RTNRPYTFGQ
101 GTKLEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV
151 DNALQSGNSQ ESVTEQDSKD STYLSSTLT LSKADYKHK VYACEVTHQG

09/284787

201 LSSPVTKSFN RGESYPYDVP DYAS

=====

HITS AT: 215-223

REFERENCE 1: 134:309702

L7 ANSWER 14 OF 52 REGISTRY COPYRIGHT 2002 ACS
RN 335072-65-6 REGISTRY
CN Immunoglobulin, anti-(human interleukin 8) (human clone M2-33
.kappa.-chain V-J-C region N-terminal fragment) (9CI) (CA INDEX
NAME)

OTHER NAMES:

CN 25: PN: WO0125492 PAGE: 100 claimed sequence

CI MAN

SQL 226

SEQ 1 EIVLTQSPGT LSLSPGERAT LSCRASQSVS SSYLAWYQQK PGQAPRLLIY
51 GASSRATGIP DRFSGSGSGT DFTLTISRLE PEDFAVYYCQ QYGSSPPYTF
101 QGGTKLEIKR TVAAPSVFIF PPSDEQLKSG TASVVCLLNN FYPREAKVQW
151 KVDNALQSGN SQESVTEQDS KDSTYLSST LTLSKADYEK HKVYACEVTH
201 QGLSSPVTKS FNRGESYPYD VPDYAS

=====

HITS AT: 217-225

REFERENCE 1: 134:309702

L7 ANSWER 15 OF 52 REGISTRY COPYRIGHT 2002 ACS
RN 335072-64-5 REGISTRY
CN Immunoglobulin, anti-(human interleukin 8) (human clone M2-32
.kappa.-chain V-J-C region N-terminal fragment) (9CI) (CA INDEX
NAME)

OTHER NAMES:

CN 24: PN: WO0125492 PAGE: 100 claimed sequence

CI MAN

SQL 224

SEQ 1 EIVLTQSPAT LSLSPGERAT LSCRASQSVS SYLAWYQQKP GQAPRLLIYD
51 ASNRAAGIPA RFSGSGSGTD FTLTISSLEP EDFAVYYCQ RNNWPLTFGG
101 GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV
151 DNALQSGNSQ ESVTEQDSKD STYLSSTLT LSKADYEKHK VYACEVTHQG
201 LSSPVTKSFN RGESYPYDVP DYAS

=====

HITS AT: 215-223

REFERENCE 1: 134:309702

L7 ANSWER 16 OF 52 REGISTRY COPYRIGHT 2002 ACS
RN 335072-63-4 REGISTRY
CN Immunoglobulin, anti-(human interleukin 8) (human clone M2-31
.kappa.-chain V-J-C region N-terminal fragment) (9CI) (CA INDEX
NAME)

OTHER NAMES:

CN 23: PN: WO0125492 PAGE: 100 claimed sequence

CN 26: PN: WO0125492 PAGE: 100 claimed sequence

CN 27: PN: WO0125492 PAGE: 100 claimed sequence

CN Immunoglobulin, anti-(human interleukin 8) (human clone M2-35
.kappa.-chain V-J-C region N-terminal fragment)

CN Immunoglobulin, anti-(human interleukin 8) (human clone M2-34

09/284787

.kappa.-chain V-J-C region N-terminal fragment)

CI MAN
SQL 224

SEQ 1 EIVLTQSPAT LSLSPGERAT LSCRASQSVS SYLAWYQQKP GQAPRLLIYD
51 ASNRATGIPA RFSGSGSGTD FTLTISSLEP EDFAVYYCQQ RTNWPRTFGQ
101 GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV
151 DNALQSGNSQ ESVTEQDSKD STYLSSTLT LSKADYEKHK VYACEVTHQG
201 LSSPVTKSFN RGESYPYDVP DYAS
=====

HITS AT: 215-223

REFERENCE 1: 134:309702

L7 ANSWER 17 OF 52 REGISTRY COPYRIGHT 2002 ACS
RN 335072-62-3 REGISTRY
CN Immunoglobulin, anti-(human interleukin 8) (human clone M2-20
.kappa.-chain V-J-C region N-terminal fragment) (9CI) (CA INDEX
NAME)

OTHER NAMES:

CN 22: PN: WO0125492 PAGE: 100 claimed sequence
CI MAN
SQL 226

SEQ 1 EIVMTQSPGT LSLSPGERAT LSCRASQSVS SSYLAWYQQK PGQAPRLLIY
51 GASRRATGIP DRFSVSGSGT DFTLTISRLE PEDFAVYYCQ QYGSSPMYTF
101 QGQTKLEIKR TVAAPSVFIF PPSDEQLKSG TASVVCLLNN FYPREAKVQW
151 KVDNALQSGN SQESVTEQDS KDSTYLSST LTLSKADYEK HKVYACEVTH
201 QGLSSPVTKS FNRGESYPYD VPDYAS
=====

HITS AT: 217-225

REFERENCE 1: 134:309702

L7 ANSWER 18 OF 52 REGISTRY COPYRIGHT 2002 ACS
RN 335072-61-2 REGISTRY
CN Immunoglobulin, anti-(human interleukin 8) (human clone M2-16
.kappa.-chain V-J-C region N-terminal fragment) (9CI) (CA INDEX
NAME)

OTHER NAMES:

CN 20: PN: WO0125492 PAGE: 100 claimed sequence
CI MAN
SQL 224

SEQ 1 EIVMTQSPGT LSLSPGERAT LSCRASQSVS SSYLAWYQQK PGQAPRLLIY
51 GASSRATGIP DRFSVSGSGT DFTLTISRLE PEDFAVYYCQ QYGSSFTFGP
101 GTKVDIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV
151 DNALQSGNSQ ESVTEQDSKD STYLSSTLT LSKADYEKHK VYACEVTHQG
201 LSSPVTKSFN RGESYPYDVP DYAS
=====

HITS AT: 215-223

REFERENCE 1: 134:309702

L7 ANSWER 19 OF 52 REGISTRY COPYRIGHT 2002 ACS
RN 335072-60-1 REGISTRY
CN Immunoglobulin, anti-(human interleukin 8) (human clone M2-12
.kappa.-chain V-J-C region N-terminal fragment) (9CI) (CA INDEX

09/284787

NAME)

OTHER NAMES:

CN 17: PN: WO0125492 PAGE: 99/100 claimed sequence

CI MAN

SQL 226

SEQ 1 EIVMTQSPGT LSLSPGERAT LSCRASQGVSSSYLAWYQQK PGQAPRLLIY
51 GASSRATGIP DRFSGSGSGT DFTLTISSE PEDFAVYYCQ QYGSSPPYTF
101 QGQTKLEIKR TVAAPSVFIF PPSDEQLKSG TASVVCLLNN FYPREAKVQW
151 KVDNALQSGN SQESVTEQDS KDSTYLSST LTLSKADYEK HKVYACEVTH
201 QGLSSPVTKS FNRGESYPYD VPDYAS
=====

HITS AT: 217-225

REFERENCE 1: 134:309702

L7 ANSWER 20 OF 52 REGISTRY COPYRIGHT 2002 ACS

RN 335072-59-8 REGISTRY

CN Immunoglobulin, anti-(human interleukin 8) (human clone M2-11
.kappa.-chain V-J-C region N-terminal fragment) (9CI) (CA INDEX
NAME)

OTHER NAMES:

CN 16: PN: WO0125492 PAGE: 99/100 claimed sequence

CI MAN

SQL 226,

SEQ 1 EIVMTQSPGT LSLSPGERAT LSCRASQGVSSSYLAWYQQK PGQAPRLLIY
51 GASSRATGIP DRFSGSGSGT DFTLTISRLE PEDFAVYYCQ QYGSSPPFTF
101 GPGTKVDIKR TVAAPSVFIF PPSDEQLRSG TASVVCLLNN FYPREAKVQW
151 KVDNALQSGN SQESVTEQDS KDSTYLSST LTLSKADYEK HKVYACEVTH
201 QGLSSPVTKS FNRGESYPYD VPDYAS
=====

HITS AT: 217-225

REFERENCE 1: 134:309702

L7 ANSWER 21 OF 52 REGISTRY COPYRIGHT 2002 ACS

RN 335072-57-6 REGISTRY

CN Immunoglobulin, anti-(human interleukin 8) (human clone M1-23
.kappa.-chain V-J-C region N-terminal fragment) (9CI) (CA INDEX
NAME)

OTHER NAMES:

CN 11: PN: WO0125492 PAGE: 98 claimed sequence

CI MAN

SQL 226

SEQ 1 EIVLTQSPGT LSLSPGERAT LSCRASQSVSSSYLAWYQQK PGQAPRLLIY
51 GASSRATGIP DRFSGSGSGT DFTLTISRLE PEDFAVYYCQ QYGSSPPYTF
101 QGQTKLEIKR TVAAPSVFIF PPSDEQLKSG TASVVCLLNN FYPREAKVQW
151 RVDNALQSGN SQESVTEQDS KDSTYLSST LTLSKADYEK HKVYACEVTH
201 QGLSSPVTKS FNRGESYPYD VPDYAS
=====

HITS AT: 217-225

REFERENCE 1: 134:309702

L7 ANSWER 22 OF 52 REGISTRY COPYRIGHT 2002 ACS

RN 335072-56-5 REGISTRY

09/284787

CN Immunoglobulin, anti-(human interleukin 8) (human clone M1-21
.kappa.-chain V-J-C region N-terminal fragment) (9CI) (CA INDEX
NAME)

OTHER NAMES:

CN 10: PN: WO0125492 PAGE: 98 claimed sequence

CI MAN

SQL 224

SEQ 1 AIRMTQSPSF LSASVGDRVT ITCRASQSIG SYLNWYQQKPK GKAPKLLIYA
51 ASSLQSGVPS RFSVSGSGTD LTLTISSLQP EDFATYYCQC GYSTPFTFGP
101 GTKVDIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV
151 DNALQSGNSQ ESVTEQDSKD STYLSSTLT LSKADYEKHK VYACEVTHQG
201 LSSPVTKSFN RGESEYPYDVP DYAS
=====

HITS AT: 215-223

REFERENCE 1: 134:309702

L7 ANSWER 23 OF 52 REGISTRY COPYRIGHT 2002 ACS

RN 335072-55-4 REGISTRY

CN Immunoglobulin, anti-(human interleukin 8) (human clone M1-10
.kappa.-chain V-J-C region N-terminal fragment) (9CI) (CA INDEX
NAME)

OTHER NAMES:

CN 8: PN: WO0125492 PAGE: 98 claimed sequence

CI MAN

SQL 224

SEQ 1 DVVMTQSPAT LSLSPGERAT LSCRASQSVS SYLAWYQQKPK GQAPRLLIYD
51 ASNRRATGIPA RFSGSGSGTD FTLTISSLEP EDFAVYYCQ RSNWPPTFGG
101 GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV
151 DNALQSGNSQ ESVTEQDSKD STYLSSTLT LSKADYEKHK VYACEVTHQG
201 LSSPVTKSFN RGESEYPYDVP DYAS
=====

HITS AT: 215-223

REFERENCE 1: 134:309702

L7 ANSWER 24 OF 52 REGISTRY COPYRIGHT 2002 ACS

RN 335072-54-3 REGISTRY

CN Immunoglobulin, anti-(human interleukin 8) (human clone M1-8
.kappa.-chain V-J-C region N-terminal fragment) (9CI) (CA INDEX
NAME)

OTHER NAMES:

CN 16: PN: WO0125492 PAGE: 98 claimed sequence

CN 21: PN: WO0125492 PAGE: 100 claimed sequence

CN Immunoglobulin, anti-(human interleukin 8) (human clone M2-18
.kappa.-chain V-J-C region N-terminal fragment)

CI MAN

SQL 224

SEQ 1 EIVMTQSPGT LSLSPGERAT LSCRASQSVS STYLAWYQQK PGQAPRLLIY
51 GASSRATGIP DRFSGSGSGT DFTLTISRLE PEDFAVYYCQ QYVSSFTFGP
101 GTKVDIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV
151 DNALQSGNSQ ESVTEQDSKD STYLSSTLT LSKADYEKHK VYACEVTHQG
201 LSSPVTKSFN RGESEYPYDVP DYAS
=====

HITS AT: 215-223

09/284787

REFERENCE 1: 134:309702

L7 ANSWER 25 OF 52 REGISTRY COPYRIGHT 2002 ACS

RN 335072-53-2 REGISTRY

CN Immunoglobulin, anti-(human interleukin 8) (human clone M1-5
.kappa.-chain V-J-C region N-terminal fragment) (9CI) (CA INDEX
NAME)

OTHER NAMES:

CN 15: PN: WO0125492 PAGE: 98 claimed sequence

CI MAN

SQL 226

SEQ 1 EIVMTQSPGT LSLSPGERAT LSCRASQSVS SSYLAWYQQK PGQAPRLLIY
51 GASSRATGIP DRFSGSGSGT DFTLTISRLE PEDFAVYYCQ QYGSSPIFTF
101 GPGTKVDIKR TVAAPSVFIF PPSDEQLKSG TASVVCLLNN FYPREAKVQW
151 KVDNALQSGN SQESVTEQDS KDSTYLSST LTLSKADYEK HKVYACEVTH
201 QGLSSPVTKS FNRGESYPYD VPDYAS
=====

HITS AT: 217-225

REFERENCE 1: 134:309702

L7 ANSWER 26 OF 52 REGISTRY COPYRIGHT 2002 ACS

RN 335072-52-1 REGISTRY

CN Immunoglobulin, anti-(human interleukin 8) (human clone M1-4
.kappa.-chain V-J-C region N-terminal fragment) (9CI) (CA INDEX
NAME)

OTHER NAMES:

CN 14: PN: WO0125492 PAGE: 98 claimed sequence

CI MAN

SQL 224

SEQ 1 EIVLTQSPGT LSLSPGERAT LSCRASQSVS SSYLAWYQQK PGQAPRLHIY
51 GASRRATGIP DRFSGSGSGT DFTLTISRLE PEDFAVYYCQ QFGSSFTFGP
101 GTKVDIKRTV AAPS VFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV
151 DNALQSGNSQ ESVTEQDSKD STYLSSTLT LSKADYEKHK VYACEVTHQG
201 LSSPVTKSFN RGESYPYDVP DYAS
=====

HITS AT: 215-223

REFERENCE 1: 134:309702

L7 ANSWER 27 OF 52 REGISTRY COPYRIGHT 2002 ACS

RN 335072-51-0 REGISTRY

CN Immunoglobulin, anti-(human interleukin 8) (human clone M1-3
.kappa.-chain V-J-C region N-terminal fragment) (9CI) (CA INDEX
NAME)

OTHER NAMES:

CN 13: PN: WO0125492 PAGE: 98 claimed sequence

CI MAN

SQL 226

SEQ 1 EIVMTQSPAT LSLSPGERAT LSCRASQSVS SSYLAWYQQK PGQAPRLLIY
51 GASSRATGIP DRFSGSGSGT DFTLTISRLE PEDFAVYYCQ QYGSSPPFTF
101 GPGTKVDIKR TVAAPSVFIF PPSDEQLKSG TASVVCLLNN FYPREAKVQW
151 KVDNALQSGN SQESVTEQDS KDSTYLSST LTLSKADYEK HKVYACEVTH
201 QGLSSPVTKS FNRGESYPYD VPDYAS

09/284787

====

HITS AT: 217-225

REFERENCE 1: 134:309702

L7 ANSWER 28 OF 52 REGISTRY COPYRIGHT 2002 ACS
RN 335072-50-9 REGISTRY
CN Immunoglobulin, anti-(human interleukin 8) (human clone M1-1
.kappa.-chain V-J-C region N-terminal fragment) (9CI) (CA INDEX
NAME)

OTHER NAMES:

CN 9: PN: WO0125492 PAGE: 98 claimed sequence

CI MAN

SQL 224

SEQ 1 EIVLTQSPAT LSLSPGERAT LSCRASQGVSYLAWYQQKP GQAPRLLIYD
51 ASNRATGIPA RFSGSGSGTD FTLTISSLEP EDFAVYYCQQ RSNWPRTFGQ
101 GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV
151 DNALQSGNSQ ESVTEQDSKD STYLSSTLT LSKADYEKHK VYACEVTHQG
201 LSSPVTKSFN RGESYPYDVP DYAS

=====

HITS AT: 215-223

REFERENCE 1: 134:309702

L7 ANSWER 29 OF 52 REGISTRY COPYRIGHT 2002 ACS
RN 324831-45-0 REGISTRY
CN (1-157)-Green fluorescent protein [endo-2-valine, 64-leucine, 65-
threonine, 147-proline] (Aequorea victoria) fusion protein with
96-108-hemagglutinin (influenza virus) fusion protein with
158-238-green fluorescent protein [231-leucine] (Aequorea victoria)
fusion protein with 96-108-hemagglutinin (influenza virus) (9CI)
(CA INDEX NAME)

CI MAN

SQL 257

SEQ 1 MVSKEELFT GVPVILVELD GDVNGHKFSV SGEGECDATY GKLTCLKFICT
51 TGKLPVPWPT LVTTLTYGVQ CFSRYPDHMK QHDFFKSAMP EGYVQERTIF
101 FKDDGNYKTR AEVKFEQDTL VNRIELKGID FKEDGNILGH KLEYNYPHN
151 VYIMADKQYP YDVPDYAKNG IKVNFKIRHN IEDGSVQLAD HYQONTPIGD

=====

201 GPVLLPDNHY LSTQSALSKD PNEKRDHMLV LEFVTAAGIT LGMDELYKYP

=====

251 YDVPDYA

=====

HITS AT: 159-167, 249-257

REFERENCE 1: 134:159864

L7 ANSWER 30 OF 52 REGISTRY COPYRIGHT 2002 ACS
RN 324831-44-9 REGISTRY
CN (1-157)-Green fluorescent protein [endo-2-valine, 64-leucine, 65-
threonine, 147-proline] (Aequorea victoria) fusion protein with
96-108-hemagglutinin (influenza virus) fusion protein with
158-172-green fluorescent protein [231-leucine] (Aequorea victoria)
fusion protein with 96-108-hemagglutinin (influenza virus) fusion
protein with 173-239-green fluorescent protein [231-leucine]
(Aequorea victoria) (9CI) (CA INDEX NAME)

09/284787

CI MAN
SQL 257

SEQ 1 MVSKEELFT GVPILVELD GDVNGHKFSV SGEGEDATY GKLTCLKFICT
51 TGKLPVPWPT LVTTLTLYGVQ CFSRYPDHMK QHDFFKSAMP EGYVQERTIF
101 FKDDGNYKTR AEVKFEGDTL VNRIELKGID FKEDGNILGH KLEYNYPHN
151 VYIMADKQYP YDVPDYAKNG IKVNFKIRHN IEYPYDVPDY ADGSVQLADH
== =====
201 YQONTPIGDG PVLLPDNHYL STQSALSKDP NEKRDHMLL EFVTAAGITL
251 GMDELYK

HITS AT: 159-167, 183-191

REFERENCE 1: 134:159864

L7 ANSWER 31 OF 52 REGISTRY COPYRIGHT 2002 ACS

RN 324831-43-8 REGISTRY

CN (1-172)-Green fluorescent protein [endo-2-valine,64-leucine,65-threonine,147-proline] (Aequorea victoria) fusion protein with 96-108-hemagglutinin (influenza virus) fusion protein with 96-108-hemagglutinin (influenza virus) fusion protein with 172-239-green fluorescent protein [231-leucine] (Aequorea victoria) (9CI) (CA INDEX NAME)

CI MAN
SQL 257

SEQ 1 MVSKEELFT GVPILVELD GDVNGHKFSV SGEGEDATY GKLTCLKFICT
51 TGKLPVPWPT LVTTLTLYGVQ CFSRYPDHMK QHDFFKSAMP EGYVQERTIF
101 FKDDGNYKTR AEVKFEGDTL VNRIELKGID FKEDGNILGH KLEYNYPHN
151 VYIMADKQKN GIKVNFKIRH NIËPYDVPD YAYPYDVPDY ADGSVQLADH
===== =
201 YQONTPIGDG PVLLPDNHYL STQSALSKDP NEKRDHMLL EFVTAAGITL
251 GMDELYK

HITS AT: 174-191

REFERENCE 1: 134:159864

L7 ANSWER 32 OF 52 REGISTRY COPYRIGHT 2002 ACS

RN 324831-42-7 REGISTRY

CN (1-157)-Green fluorescent protein [endo-2-valine,64-leucine,65-threonine,147-proline] (Aequorea victoria) fusion protein with 96-108-hemagglutinin (influenza virus) fusion protein with 96-108-hemagglutinin (influenza virus) fusion protein with 158-239-green fluorescent protein [231-leucine] (Aequorea victoria) (9CI) (CA INDEX NAME)

CI MAN
SQL 257

SEQ 1 MVSKEELFT GVPILVELD GDVNGHKFSV SGEGEDATY GKLTCLKFICT
51 TGKLPVPWPT LVTTLTLYGVQ CFSRYPDHMK QHDFFKSAMP EGYVQERTIF
101 FKDDGNYKTR AEVKFEGDTL VNRIELKGID FKEDGNILGH KLEYNYPHN
151 VYIMADKQYP YDVPDYAYPY DVPDYAKNGI KVNFKIRHNI EDGSVQLADH
===== =
201 YQONTPIGDG PVLLPDNHYL STQSALSKDP NEKRDHMLL EFVTAAGITL
251 GMDELYK

HITS AT: 159-176

REFERENCE 1: 134:159864

09/284787

L7 ANSWER 33 OF 52 REGISTRY COPYRIGHT 2002 ACS
RN 324831-41-6 REGISTRY
CN (1-157)-Green fluorescent protein [endo-2-valine,64-leucine,65-threonine,147-proline] (Aequorea victoria) fusion protein with 96-108-hemagglutinin (influenza virus) fusion protein with 158-239-green fluorescent protein [231-leucine] (Aequorea victoria) (9CI) (CA INDEX NAME)
CI MAN
SQL 248

SEQ 1 MVSKGEELFT GVPILVELD GDVNGHKFSV SGEGEDATY GKLTCLKFICT
51 TGKLPVPWPT LVTTLTYGVO CFSRYPDHMK QHDFFKSAMP EGYVQERTIF
101 FKDDGNYKTR AEVKFEGDTL VNRIELKGID FKEDGNILGH KLEYNYNPHN
151 VYIMADKQYP YDVPDYAKNG IKVNFKIRHN IEDGSVQLAD HYQNTPIGD
== =====
201 GPVLLPDNHY LSTQSALSKD PNEKRDHMLV LEFVTAAGIT LGMDLYK
HITS AT: 159-167

REFERENCE 1: 134:159864

L7 ANSWER 34 OF 52 REGISTRY COPYRIGHT 2002 ACS
RN 324831-40-5 REGISTRY
CN (1-172)-Green fluorescent protein [endo-2-valine,64-leucine,65-threonine,147-proline] (Aequorea victoria) fusion protein with 96-108-hemagglutinin (influenza virus) fusion protein with 173-239-green fluorescent protein [231-leucine] (Aequorea victoria) (9CI) (CA INDEX NAME)
CI MAN
SQL 248

SEQ 1 MVSKGEELFT GVPILVELD GDVNGHKFSV SGEGEDATY GKLTCLKFICT
51 TGKLPVPWPT LVTTLTYGVO CFSRYPDHMK QHDFFKSAMP EGYVQERTIF
101 FKDDGNYKTR AEVKFEGDTL VNRIELKGID FKEDGNILGH KLEYNYNPHN
151 VYIMADKQKN GIKVNFKIRH NIEYPYDVPD YADGSVQLAD HYQNTPIGD
===== ==
201 GPVLLPDNHY LSTQSALSKD PNEKRDHMLV LEFVTAAGIT LGMDLYK
HITS AT: 174-182

REFERENCE 1: 134:159864

L7 ANSWER 35 OF 52 REGISTRY COPYRIGHT 2002 ACS
RN 282119-67-9 REGISTRY
CN Antibody-binding protein (synthetic clone pSEX11G2) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 4: PN: DE19900635 FIGURE: 2 claimed sequence
CI MAN
SQL 228

SEQ 1 METDTLLLVV LLLWVPGSTG DYPYDVPDYA GAQKPEVIDA SELTPAVTTY
=====
51 KLVINGKTLK GETTTEAVDA ATAELVKFQY ANDNGVDGEW TYDDATKTFT
101 VTEKPEVIDA SELTPAVTTY KLVINGKTLK GETTTEAVDA ATAELVKFQY
151 ANDNGVDGEW TYDDATKTFT VTEAAAEQKL ISEEDLNGAV DGQNDTSQTS
201 SPSASSNISG GIFLFFVANA IIHLFCFS
HITS AT: 22-30

REFERENCE 1: 133:103704

09/284787

L7 ANSWER 36 OF 52 REGISTRY COPYRIGHT 2002 ACS

RN 217323-97-2 REGISTRY

CN L-Arginine, L-seryl-L-lysyl-L-tyrosyl-L-prolyl-L-tyrosyl-L-.alpha.-
aspartyl-L-valyl-L-prolyl-L-.alpha.-aspartyl-L-tyrosyl-L-alanyl-L-
arginyl-L-arginyl- (9CI) (CA INDEX NAME)

SQL 14

SEQ 1 SKYPYDVPDY ARRR

=====

HITS AT: 3-11

REFERENCE 1: 130:47580

L7 ANSWER 37 OF 52 REGISTRY COPYRIGHT 2002 ACS

RN 214681-43-3 REGISTRY

CN L-Serine, N-(3-mercapto-1-oxopropyl)-L-tyrosyl-L-prolyl-L-tyrosyl-L-
.alpha.-aspartyl-L-valyl-L-prolyl-L-.alpha.-aspartyl-L-tyrosyl-L-
alanyl- (9CI) (CA INDEX NAME)

SQL 10

SEQ 1 YPYDVPDYAS

=====

HITS AT: 1-9

REFERENCE 1: 129:313112

L7 ANSWER 38 OF 52 REGISTRY COPYRIGHT 2002 ACS

RN 206654-13-9 REGISTRY

CN L-Alaninamide, N-[6-[[5-[(3aS,4S,6aR)-hexahydro-2-oxo-1H-thieno[3,4-
d]imidazol-4-yl]-1-oxopentyl]amino]-1-oxohexyl]-L-serylglycyl-L-
serylglycyl-L-tyrosyl-L-prolyl-L-tyrosyl-L-.alpha.-aspartyl-L-valyl-
L-prolyl-L-.alpha.-aspartyl-L-tyrosyl- (9CI) (CA INDEX NAME)

SQL 14

SEQ 1 XSGSGYPYDV PDYA

=====

HITS AT: 6-14

REFERENCE 1: 128:307529

L7 ANSWER 39 OF 52 REGISTRY COPYRIGHT 2002 ACS

RN 206654-11-7 REGISTRY

CN L-Lysinamide, N-acetyl-L-tyrosyl-L-prolyl-L-tyrosyl-L-.alpha.-
aspartyl-L-valyl-L-prolyl-L-.alpha.-aspartyl-L-tyrosyl-L-
alanylglycyl-L-serylglycyl-L-seryl-N6-[5-[(3aS,4S,6aR)-hexahydro-2-
oxo-1H-thieno[3,4-d]imidazol-4-yl]-1-oxopentyl]- (9CI) (CA INDEX
NAME)

SQL 14

SEQ 1 YPYDVPDYAG SGSK

=====

HITS AT: 1-9

REFERENCE 1: 128:307529

L7 ANSWER 40 OF 52 REGISTRY COPYRIGHT 2002 ACS

RN 133373-26-9 REGISTRY

09/284787

CN L-Alanine, N-[N-[N-[1-[N-[N-[N-[1-[N-(acetyl-t)-L-tyrosyl]-2-methyl-L-prolyl]-L-tyrosyl]-L-.alpha.-aspartyl]-L-valyl]-L-prolyl]-L-.alpha.-aspartyl]-L-tyrosyl]- (9CI) (CA INDEX NAME)

SQL 9

SEQ 1 YPYDVDPDYA

=====

HITS AT: 1-9

REFERENCE 1: 115:92883

L7 ANSWER 41 OF 52 REGISTRY COPYRIGHT 2002 ACS

RN 133373-25-8 REGISTRY

CN L-Alanine, N-[N-[N-[1-[N-[N-[N-[1-[N-(acetyl-t)-L-tyrosyl]-L-prolyl]-L-tyrosyl]-L-.alpha.-aspartyl]-L-valyl]-L-prolyl]-L-.alpha.-aspartyl]-L-tyrosyl]- (9CI) (CA INDEX NAME)

SQL 9

SEQ 1 YPYDVDPDYA

=====

HITS AT: 1-9

REFERENCE 1: 115:92883

L7 ANSWER 42 OF 52 REGISTRY COPYRIGHT 2002 ACS

RN 133373-22-5 REGISTRY

CN L-Alanine, N-[N-[N-[1-[N-[N-[N-[1-(N-acetyl-L-tyrosyl)-L-prolyl]-N-methyl-L-tyrosyl]-L-.alpha.-aspartyl]-L-valyl]-L-prolyl]-L-.alpha.-aspartyl]-L-tyrosyl]- (9CI) (CA INDEX NAME)

SQL 9

SEQ 1 YPYDVDPDYA

=====

HITS AT: 1-9

REFERENCE 1: 115:92883

L7 ANSWER 43 OF 52 REGISTRY COPYRIGHT 2002 ACS

RN 130203-49-5 REGISTRY

CN L-Alanine, N-[N-[N-[1-[N-[N-[N-[1-(N-acetyl-L-tyrosyl)-2-methyl-L-prolyl]-L-tyrosyl]-L-.alpha.-aspartyl]-L-valyl]-L-prolyl]-L-.alpha.-aspartyl]-L-tyrosyl]- (9CI) (CA INDEX NAME)

SQL 9

SEQ 1 YPYDVDPDYA

=====

HITS AT: 1-9

REFERENCE 1: 115:92883

REFERENCE 2: 115:69641

REFERENCE 3: 113:189276

L7 ANSWER 44 OF 52 REGISTRY COPYRIGHT 2002 ACS

RN 129970-92-9 REGISTRY

CN L-Alanine, N-[N-[N-[1-[N-[N-[N-[1-(N-acetyl-L-tyrosyl)-L-prolyl]-L-tyrosyl]-L-.alpha.-aspartyl]-L-valyl]-L-prolyl]-L-.alpha.-aspartyl]-

09/284787

L-tyrosyl]- (9CI) (CA INDEX NAME)
SQL 9

SEQ 1 YPYDVPDYA

=====

HITS AT: 1-9

REFERENCE 1: 115:92883

REFERENCE 2: 115:69641

REFERENCE 3: 113:168330

L7 ANSWER 45 OF 52 REGISTRY COPYRIGHT 2002 ACS

RN 122580-22-7 REGISTRY

CN L-Serine, L-tyrosyl-L-prolyl-L-tyrosyl-L-.alpha.-aspartyl-L-valyl-L-prolyl-L-.alpha.-aspartyl-L-tyrosyl-L-alanyl- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN L-Serine, N-[N-[N-[N-[1-[N-[N-[N-(1-L-tyrosyl-L-prolyl)-L-tyrosyl]-L-.alpha.-aspartyl]-L-valyl]-L-prolyl]-L-.alpha.-aspartyl]-L-tyrosyl]-L-alanyl]-

OTHER NAMES:

CN 14: PN: US6258527 SEQID: 12 unclaimed sequence

CN 195: PN: WO0125492 PAGE: 80 unclaimed sequence

CN 21: PN: WO0078815 PAGE: 82 unclaimed sequence

CN 23: PN: US20010011125 SEQID: 23 unclaimed sequence

CN 27: PN: WO0127157 SEQID: 23 unclaimed sequence

SQL 10

SEQ 1 YPYDVPDYAS

=====

HITS AT: 1-9

REFERENCE 1: 135:151636

REFERENCE 2: 135:103329

REFERENCE 3: 134:309702

REFERENCE 4: 134:305781

REFERENCE 5: 134:70371

REFERENCE 6: 131:254328

REFERENCE 7: 129:326944

REFERENCE 8: 129:313112

REFERENCE 9: 117:70187

L7 ANSWER 46 OF 52 REGISTRY COPYRIGHT 2002 ACS

RN 122580-21-6 REGISTRY

CN L-Leucine, L-tyrosyl-L-prolyl-L-tyrosyl-L-.alpha.-aspartyl-L-valyl-L-prolyl-L-.alpha.-aspartyl-L-tyrosyl-L-alanyl-L-seryl- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN L-Leucine, N-[N-[N-[N-[1-[N-[N-[N-(1-L-tyrosyl-L-prolyl)-L-

09/284787

tyrosyl]-L-.alpha.-aspartyl]-L-valyl]-L-prolyl]-L-.alpha.-aspartyl]-
L-tyrosyl]-L-alanyl]-L-seryl]-

OTHER NAMES:

CN PN: WO9951625 PAGE: 13 unclaimed sequence

SQL 11

SEQ 1 YPYDVDPDYAS L

=====

HITS AT: 1-9

REFERENCE 1: 135:119192

REFERENCE 2: 131:296841

REFERENCE 3: 111:132040

L7 ANSWER 47 OF 52 REGISTRY COPYRIGHT 2002 ACS

RN 122580-20-5 REGISTRY

CN L-Arginine, N2-[N-[N-[N-[N-[N-[N-[N-(1-L-tyrosyl-L-prolyl)-L-
tyrosyl]-L-.alpha.-aspartyl]-L-valyl]-L-prolyl]-L-.alpha.-aspartyl]-
L-tyrosyl]-L-alanyl]-L-seryl]-L-leucyl]- (9CI) (CA INDEX NAME)

SQL 12

SEQ 1 YPYDVDPDYAS LR

=====

HITS AT: 1-9

REFERENCE 1: 111:132040

L7 ANSWER 48 OF 52 REGISTRY COPYRIGHT 2002 ACS

RN 92000-76-5 REGISTRY

CN L-Alanine, L-tyrosyl-L-prolyl-L-tyrosyl-L-.alpha.-aspartyl-L-valyl-L-
prolyl-L-.alpha.-aspartyl-L-tyrosyl- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN L-Alanine, N-[N-[N-[1-[N-[N-[N-(1-L-tyrosyl-L-prolyl)-L-tyrosyl]-L-
.alpha.-aspartyl]-L-valyl]-L-prolyl]-L-.alpha.-aspartyl]-L-tyrosyl]-

OTHER NAMES:

CN 105: PN: WO0026408 SEQID: 38 claimed protein

CN 10: PN: WO0105998 SEQID: 20 unclaimed sequence

CN 10: PN: WO0114404 SEQID: 10 unclaimed sequence

CN 10: PN: WO0185962 SEQID: 10 unclaimed sequence

CN 113: PN: WO0050872 SEQID: 38 unclaimed sequence

CN 13: PN: WO0014229 PAGE: 31 unclaimed sequence

CN 13: PN: WO0034308 PAGE: 60 unclaimed sequence

CN 14: PN: WO0162968 SEQID: 2 unclaimed sequence

CN 17: PN: WO0168141 PAGE: 35 unclaimed sequence

CN 19: PN: WO0158935 PAGE: 42 unclaimed sequence

CN 1: PN: US6300065 SEQID: 1 unclaimed sequence

CN 202: PN: WO0185946 SEQID: 202 unclaimed sequence

CN 21: PN: WO0179561 SEQID: 23 unclaimed sequence

CN 24: PN: WO0177151 SEQID: 24 unclaimed sequence

CN 24: PN: WO0196579 SEQID: 25 unclaimed sequence

CN 2: PN: WO0172458 PAGE: 27 unclaimed sequence

CN 36: PN: US6083706 SEQID: 36 unclaimed sequence

CN 3: PN: US6017692 SEQID: 6 unclaimed sequence

CN 3: PN: US6306613 SEQID: 36 unclaimed sequence

CN 3: PN: WO0101137 SEQID: 3 unclaimed sequence

CN 3: PN: WO0206327 SEQID: 4 unclaimed sequence

09/284787

CN 41: PN: WO0136001 PAGE: 30 unclaimed sequence
CN 51: PN: WO0114578 PAGE: 47 unclaimed sequence
CN 5: PN: JP2001299357 PAGE: 8 unclaimed sequence
CN 5: PN: WO0023622 SEQID: 9 unclaimed sequence
CN 5: PN: WO0042166 PAGE: 6 unclaimed sequence
CN 5: PN: WO0132894 SEQID: 5 claimed sequence
CN 5: PN: WO0166745 SEQID: 6 unclaimed sequence
CN 75: PN: WO0206834 PAGE: 35 unclaimed sequence
CN 7: PN: WO0135072 TABLE: 1 unclaimed sequence
CN 8: PN: WO0158493 PAGE: 38 unclaimed sequence
CN 9: PN: EP1022287 SEQID: 5 unclaimed sequence
CN 9: PN: US5989893 SEQID: 3 unclaimed protein
CN 9: PN: WO0056926 SEQID: 9 unclaimed sequence
CN 9: PN: WO0109292 SEQID: 3 unclaimed sequence
CN 9: PN: WO0158950 PAGE: 29 unclaimed sequence
CN PN: US5962311 SEQID: 11 unclaimed sequence
SQL 9

SEQ 1 YPYDVDPDYA

=====

HITS AT: 1-9

REFERENCE 1: 136:221696

REFERENCE 2: 136:212778

REFERENCE 3: 136:162371

REFERENCE 4: 136:146224

REFERENCE 5: 136:146223

REFERENCE 6: 136:131193

REFERENCE 7: 136:116835

REFERENCE 8: 136:65233

REFERENCE 9: 135:368551

REFERENCE 10: 135:367755

L7 ANSWER 49 OF 52 REGISTRY COPYRIGHT 2002 ACS

RN 92000-73-2 REGISTRY

CN L-Serine, L-tyrosyl-L-prolyl-L-tyrosyl-L-.alpha.-aspartyl-L-valyl-L-prolyl-L-.alpha.-aspartyl-L-tyrosyl-L-alanyl-L-seryl-L-leucyl-L-arginyl- (9CI) (CA INDEX NAME)

SQL 13

SEQ 1 YPYDVDPDYAS LRS

=====

HITS AT: 1-9

REFERENCE 1: 136:101015

REFERENCE 2: 123:193068

REFERENCE 3: 121:228304

09/284787

REFERENCE 4: 111:132040

REFERENCE 5: 109:226016

REFERENCE 6: 107:154735

REFERENCE 7: 106:82706

REFERENCE 8: 101:149419

L7 ANSWER 50 OF 52 REGISTRY COPYRIGHT 2002 ACS

RN 92000-68-5 REGISTRY

CN L-Serine, L-valyl-L-.alpha.-glutamyl-L-arginyl-L-seryl-L-lysyl-L-alanyl-L-phenylalanyl-L-seryl-L-asparaginyl-L-cysteinyl-L-tyrosyl-L-prolyl-L-tyrosyl-L-.alpha.-aspartyl-L-valyl-L-prolyl-L-.alpha.-aspartyl-L-tyrosyl-L-alanyl-L-seryl-L-leucyl-L-arginyl- (9CI) (CA INDEX NAME)

SQL 23

SEQ 1 VERSKAFSNC YPYDVDPDYAS LRS

HITS AT: 11-19

REFERENCE 1: 111:132040

REFERENCE 2: 106:3593

REFERENCE 3: 101:149419

L7 ANSWER 51 OF 52 REGISTRY COPYRIGHT 2002 ACS

RN 87244-32-4 REGISTRY

CN L-Serine, L-histidyl-L-cysteinyl-L-.alpha.-aspartylglycyl-L-phenylalanyl-L-glutamyl-L-asparaginyl-L-.alpha.-glutamyl-L-lysyl-L-tryptophyl-L-.alpha.-aspartyl-L-leucyl-L-phenylalanyl-L-valyl-L-.alpha.-glutamyl-L-arginyl-L-seryl-L-lysyl-L-alanyl-L-phenylalanyl-L-seryl-L-asparaginyl-L-cysteinyl-L-tyrosyl-L-prolyl-L-tyrosyl-L-.alpha.-aspartyl-L-valyl-L-prolyl-L-.alpha.-aspartyl-L-tyrosyl-L-alanyl-L-seryl-L-leucyl-L-arginyl- (9CI) (CA INDEX NAME)

CI MAN

SQL 36

SEQ 1 HCDGFQNEKW DLFVERSKAF SNCYPYDVPD YASLRS

HITS AT: 24-32

REFERENCE 1: 106:3593

REFERENCE 2: 101:149419

REFERENCE 3: 99:137927

L7 ANSWER 52 OF 52 REGISTRY COPYRIGHT 2002 ACS

RN 76082-66-1 REGISTRY

CN Hemagglutinin (influenza virus A/Aichi/2/68 clone X31 precursor protein moiety reduced) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN Hemagglutinin (influenza virus A/Hong Kong/1/68 precursor protein

09/284787

moiety reduced)

CN Hemagglutinin (influenza virus strain A2/Aichi/2/68 precursor)
CI MAN
SQL 566

SEQ 1 MKTIIALSYI FCLALGQDLP GNDNSTATLC LGHHAVPNGT LVKTITDDQI
51 EVTNATELVQ SSSTGKICNN PHRILDGIDC TLIDALLGDP HCDVFQNETW
101 DLFVERSKAF SNCYPYDVPD YASLRSLVAS SGTLEFITEG FTWTGVTQNG
===== ==
151 GSNACKRGP GSGFFSRLNLW TKSGSTYPVL NVTMPNNDNF DKLYIWGIHH
201 PSTNQEQTS YVQASGRVTV STRRSQQTII PNIGSRPWVR GLSSRISIYW
251 TIVKPGDVLV INSNGNLIAP RGYFKMRTGK SSIMRSDAPI DTCISECITP
301 NGSIPNDKPF QNVNKITYGA CPKYVKQNTL KLATGMRNVP EKQTRGLFGA
351 IAGFIENGWE GMIDGWYGFH HQNSEGTGQA ADLKSTQAAI DQINGKLN RV
401 IEKTNEKFHQ IEKEFSEVEG RIQDLEKYVE DTKIDLWSYN AELLVALENQ
451 HTIDLT DSEM NKLFEKTRRQ LRENAEEMGN GCFKIYHKCD NACIESIRNG
501 TYDHDVYRDE ALNNRFQIKG VELKSGYKDW ILWISFAISC FLLCVVLLGF
551 IMWACQRGNI RCNICI

HITS AT: 114-122

REFERENCE 1: 122:185340

REFERENCE 2: 96:80621

REFERENCE 3: 94:27186

FILE 'HOME' ENTERED AT 09:24:33 ON 12 APR 2002

FILE 'CAPIUS' ENTERED AT 09:36:59 ON 12 APR 2002

L8 1 S L2 AND 10#(2W)M#
L9 0 S L8 NOT L5